First insights for targeted therapies in odontogenic myxoma
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Minas Gerais
Descrição
Tipo
Artigo de periódico
Título alternativo
Primeiro orientador
Membros da banca
Resumo
Objective: Odontogenic myxoma (OM) occasionally responds poorly to surgical treatment. The MAPK pathway is constitutively activated in several neoplasms and we aimed to test if the MAPK pathway is activated in OM, in order to pave the way for an alternative therapy for aggressive and recurrent cases.
Materials and methods: The immunoexpression of phosphorylated ERK1/2 (pERK1/2) was assessed in OM. We established a 3D organotypic culture model for the in vitro study and patient-derived xenografts (PDX) in mice for the in vivo study. The MEK inhibitor U0126 was used to inhibit phosphorylation of ERK1/2 in the in vitro and in vivo models.
Results: All OM showed strong pERK1/2 immunoexpression, consistent with MAPK pathway activation. Treatment of the 3D culture with U0126 resulted in a reduced pERK1/2/ERK1/2 ratio. Consistent with the in vitro results, all PDX of animals treated with U0126 showed a decreased volume fold change compared with controls.
Conclusions: The MAPK pathway is activated in OM and its inhibition leads to tumor shrinkage in PDX and cell culture models.
Clinical relevance: Our results offer a pre-clinical frame for OM-targeted therapy. Further work is needed to determine if this initial finding holds clinical promise.
Abstract
Assunto
Cell culture techniques, three dimensional, Mitogen-activated protein kinase kinases, Extracellular signal-regulated MAP kinases, MAP kinase signaling system, MAP kinase kinase kinases, Odontogenic tumors, Heterografts, Therapeutics
Palavras-chave
3D cell culture, ERK, MAPK pathway, MEK inhibition, Odontogenic tumors, PDX, Targeted therapy
Citação
Curso
Endereço externo
https://link.springer.com/article/10.1007/s00784-019-03107-4